Catechol-O-methyl transferase (COMT) inhibitors in patients with Parkinson's disease: Is COMT genotype a useful indicator of clinical efficacy?

American Journal of PharmacoGenomics

Volumn 3, Issue 1, 2003, Pages 11-15

  Rinne, Juha O ^a   Ulmanen, Ismo ^b   Lee, Myung Sik ^c  

^a UNIVERSITY OF TURKU   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; TOLCAPONE;

CHROMOSOME 22; CHROMOSOME ARM; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; GENE CONTROL; GENETIC VARIABILITY; GENOTYPE; HUMAN; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANIMALS; CATECHOL O-METHYLTRANSFERASE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HUMANS; PARKINSON DISEASE;

EID: 0037219072     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200303010-00003     Document Type: Review

References (43)

1. Nutt J, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996; 39: 561-73
2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesia and motor fluctuation as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58
3. Fahn S. The spectrum of levodopa induced dyskinesias. Ann Neurol 2000; 47 Suppl. 1: S2-S11
4. Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27: 135-206
5. Dingemanse J. Issues important for rational COMT inhibition. Neurology 2000; 55 Suppl. 4: S24-7
6. Salminen M, Lundström K, Tilgmann C, et al. Molecular cloning and characterization of rat liver catechol-O-methyltransferase, Gene 1990; 93: 241-5
7. Bertocci B, Miggiano V, Da Prada M, et al. Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc Natl Acad Sci U S A 1991; 88: 1416-20
8. Lundström K, Salminen M, Jalanko A, et al. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol 1991; 10: 181-9
9. Brahe C, Bannetta P, Meera Khan P, et al. Assignment of the catechol-O-methyltransferase gene to human chromosome 22 in somatic cell hybrids. Hum Genet 1986; 74 (3): 230-4
10. Grossman MH, Emanuel BS, Budarf ML. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics 1992; 12 (4): 822-5
11. Winqvist R, Lundström K, Salminen M, et al. The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BgII. Cytogenet Cell Genet 1992; 59: 253-7
12. Ulmanen I, Peránen J, Tenhunen J, et al. Expression and intracellular localization of catechol O-methyltransferase (COMT) in transfected mammalian cells. Eur J Biochem 1997; 243: 452-9
13. Weisz J, Fritz-Wolz G, Gestl S, et al. Nuclear localization of catechol-O-methyltransferase in neoplastic and nonneoplastic mammary epithelial cells. Am J Pathol 2000; 156: 1841-8
14. Karhunen T, Tilgmann C, Ulmanen I, et al. Distribution of catechol-O-methyltransferase in rat tissues. J Histochem Cytochem 1994; 42: 1079-90
15. Tenhunen J, Salminen M, Lundström K, et al. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 1994; 223: 1049-59
16. Lundström K, Tenhunen J, Tilgmann C, et al. Cloning, expression and structure of catechol-O-methyltransferase. Biochem Biophys Acta 1995; 125: 1-10
17. Weisz J, Fritz-Wolz G, Clawson GA, et al. Induction of nuclear catechol-O-methyltransferase by estrogens in hamster kidney: implications for estrogen-induced renal cancer. Carcinogenesis 1998; 19: 1307-12
18. Weinshilboum RM. Human biochemical genetics of plasma dopamine-beta-hydroxylase and erythrocyte catechol-O-methyltransferase. Hum Genet 1978; Suppl. 1: 101-12
19. Scanlon PD, Raymond FA, Weinshilboum RM. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science 1979; 203: 63-5
20. Boudïková B, Szumlanski C, Maidak B, et al. Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 1990; 48: 381-9
21. Lachman HM, Papolos DF, Saito T, et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-50
22. Syvänen AC, Tilgmann C, Rinne JO, et al. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 1997; 7: 65-71
23. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202-10
24. Vidgren J, Svensson LA, Liljas A. Crystal structure of catechol O-methyltransferase. Nature 1994; 368: 354-8
25. Kinnear C, Niehaus DJ, Seedat S, et al. Obsessive-compulsive disorder and a novel polymorphism adjacent to the oestrogen response element (ERE 6) upstream from the COMT gene. Psychiatr Genet 2001; 11; 85-7
26. Rivera-Calimlim L, Reilly DK. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance. Clin Pharmacol Ther 1984; 35: 804-9
27. Klemetsdal B, Straume B, Giverhaug T, et al. Low catechol-O-methyltransferase activity in a Saami population. Eur J Clin Pharmacol 1994; 46: 231-5
28. McLeod HL, Fang L, Luo X, et al. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther 1994; 270: 26-9
29. Karayiorgou M, Altemus M, Galke BL, et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci U S A 1997; 94: 4572-5
30. Palmatier MA, Kang AM, Kidd KK. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol Psychiatry 1999; 46: 557-67
31. Ameyaw MM, Syvanen AC, Ulmanen I, et al. Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian population. Hum Mutat 2000; 16: 445-6
32. Kocabas NA, Karakaya AE, Cholerton S, et al. Catechol-O-methyltransferase (COMT) genetic polymorphism in a Turkish population. Arch Toxicol 2001; 75: 407-9
33. Weinshilboum RM. Human erythrocyte catechol-o-methyl transferase: correlation with lung and kidney activity. Life Sci 1978; 22: 625-30
34. Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994; 46: 151-7
35. Ruottinen HM, Ulmanen I, Gordin A, et al. COMT genotype and response to levodopa in Parkinson's disease: influence of COMT inhibition with entacapone [abstract]. Mov Disord 1998; 13 Suppl. 2: 120
36. Routtinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996; 19: 283-96
37. Weiss JL, Cohn CK, Chase TN. Reduction of catechol-O-methyl-transferase activity by chronic levodopa treatment. Nature 1971; 234: 218-9
38. Lee MS, Kim HS, Cho EK, et al. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 2002; 58: 564-7
39. McLeod H, Syvänen AC, Githang'a J, et al. Ethnic differences in catechol-O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or south-west Asian individuals. Pharmacogenetics 1998; 8: 195-9
40. Rivett AJ, Fracis A, Roth JA. Localization of membrane-bound catechol-O-methyltransferase. J Neurochem 1983; 40: 1494-6
41. Chong DJ, Suchowersky O, Szumlanski C, et al. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 2000; 23: 143-8
42. Evans MA, Broe GA, Triggs EJ, et al. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patients. Neurology 1981; 31: 1288-94
43. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996; 60: 36-40